Canine parvovirus cDNA and recombinant antigen

Canine parvovirus (CPV) is a highly contagious virus that infects dogs. It belongs to the Parvoviridae family and is also known as canine parvovirus type 2 (CPV-2). CPV primarily attacks the gastrointestinal tract, leading to symptoms such as vomiting, diarrhea, and dehydration. In puppies, CPV can also infect the heart muscle and cause myocarditis. The virus spreads through contact with contaminated feces, urine, or vomit. CPV has a genome that is approximately 5 kilobases in length and is a single-stranded DNA molecule. It encodes several proteins that play roles in replication and evasion of host immunity. Currently, there is no specific cure for CPV infections, and management is primarily supportive.

CPV’s genome is a non-enveloped virus that comprises a single strand of circular DNA. The genetic information in CPV’s genome is critical to the virus’s ability to infect and replicate in dogs, as well as the development of disease symptoms.

The CPV antigen refers to any substance that triggers an immune response in an infected dog. The CPV antigen comprises viral proteins present on the virus’s surface or produced during replication. The dog’s immune system recognizes these antigens and produces antibodies that neutralize the virus. Antigens are essential in the development of vaccines, as they stimulate the immune system and protect against future CPV infections. Vaccination with CPV antigens is highly recommended for all dogs and is an effective way to prevent infections with this virus.

Nonstructural protein 2, also known as NS2, is a viral protein that plays a role in viral replication and is involved in the regulation of viral gene expression.

VP1 and VP2 are viral structural proteins that form the capsid of the virus, which protects the viral genome and facilitates viral entry into host cells. VP2 is the major capsid protein, while VP1 is a minor capsid protein that plays a role in viral infectivity.

It is important to note that canine parvovirus has a relatively small genome and encodes only a few proteins, which play essential roles in viral replication and pathogenesis. Other canine parvovirus proteins include the nonstructural protein NS1, which is involved in viral replication and gene expression, and the phosphoprotein NS3, which is involved in the regulation of viral gene expression and in modulating the host immune response.

Understanding the functions of these key proteins is important for understanding the pathogenesis of CPV and developing effective treatments and prevention strategies. The VP2 protein has been the target of many diagnostic tests and vaccines due to its important role in the virus capsid. Additionally, research into the interactions between these proteins and the host immune system may lead to new therapies for other Parvoviridae infections in both humans and animals.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.